Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One spider session: does fear stay away for months?

NCT ID NCT06255821

Knowledge-focused Sponsor: Ruhr University of Bochum Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a single session of facing a live spider can reduce fear and disgust, and if that benefit lasts up to three months. Fifty-nine people with spider fear participated. They were tested with the same spider and a new spider at different follow-up times to see if the fear reduction spreads.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Exposure therapy (one session of graded in-vivo exposure with a spider)
What this could lead to
If successful, this could help refine exposure therapy for phobias by showing how long benefits last and whether they apply to new spiders.
What could go wrong
This is a small, completed study with only 59 participants. Results may not apply to everyone with spider fear, and the effect may fade over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

59 people

The number who actually took part.

Started

Jul 2024

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Presence of fear of spiders (Potential diagnosis of arachnophobia) Exclusion Criteria: * Reaching level 10 or higher in the initial (Pre-Exposure) Spider BAT * Any acute or chronic mental and / or somatic disease * Psychological, psychiatric, neurological or pharmacological treatment * Drug or alcohol abuse * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for One week follow-up assessment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety disorder Arachnophobia specific phobia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

One week follow-up assessment Six weeks follow-up assessment Three months follow-up assessment

Contacts and locations

Locations

  • Department of Behavioral and Clinical Neuroscience

    Bochum, 44787, Germany